Currently Viewing:
Newsroom
Currently Reading
Nearly Half of New Drugs Approved in 2016 Were Orphan Drugs
January 17, 2017 – Laura Joszt
Safety of Januvia in Oldest Patients With Diabetes Confirmed in Study
January 16, 2017 – Mary Caffrey
Patient and Provider Education on Pain in Cancer: A Cost-Saving Intervention
January 16, 2017 – Surabhi Dangi-Garimella, PhD
Overlap of Nonadherence to COPD Medications and Other Chronic Disease Medications
January 14, 2017 – Laura Joszt
Initiative to Aid the Fight Against Rare Diseases
January 14, 2017 – AJMC Staff
CMS Takes Step Toward Coverage of Continuous Glucose Monitors
January 13, 2017 – Mary Caffrey
The Burden of Being a Medicare Patient With NSCLC
January 12, 2017 – Surabhi Dangi-Garimella, PhD
Joint Statement by 69 Cancer Centers Supports CDC's HPV Vaccination Guideline
January 12, 2017 – Surabhi Dangi-Garimella, PhD
NCI Formulary a Big Support for Cancer Moonshot
January 11, 2017 – Surabhi Dangi-Garimella, PhD

Nearly Half of New Drugs Approved in 2016 Were Orphan Drugs

Laura Joszt
Among the 9 new orphan drugs approved by the FDA in 2016 were 3 treatments for rare diseases that, so far, had no approved treatments: Duchenne muscular dystrophy, spinal muscular atrophy, and severe hepatic veno-occlusive disease.
Close to half (41%) of the new medications approved by the FDA in 2016 were orphan drugs, according to the National Organization for Rare Diseases (NORD). Among the 9 new orphan drugs were 3 treatments for rare diseases that, so far, had no approved treatments: Duchenne muscular dystrophy, spinal muscular atrophy, and severe hepatic veno-occlusive disease.

The high percentage of orphan drugs being approved by the FDA is welcome news for the 30 million Americans who have a rare disease, said Peter L. Saltonstall, president and CEO of NORD.

“At the same time, we must recognize that our patient community faces new challenges in accessing many new therapies, and that the vast majority of the 7000 rare diseases still have no treatment options,” he said in a statement. “We look forward to still more progress in 2017 and beyond.”

While the overall number of drugs approved in 2016 was lower than the previous year, the majority (73%) of those that were approved benefitted from one of the FDA’s programs to expedite the process of drug review, such as breakthrough therapy designation or priority review designation. In addition, nearly all (95%) of new products were approved during the “first cycle” without any delays to approval, John Jenkins, MD, who recently retired from his position as director of the Office of New Drugs at the FDA, wrote in a blog post.

“Moreover, 86% of the novel drug approvals were approved in the U.S. before they were approved by any other regulatory authorities,” he wrote.

Even though there were fewer drugs approved than the average 29 approvals per year over the last decade, the way drugs were approved show that the Center for Drug Evaluation and Research is reviewing drugs as quickly as possible.

“We thank the FDA for its continued flexibility in reviewing applications that often include small studies due to the small number of patients with the disease,” Saltonstall said.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up